| Autor: |
Wang, Jingbo, Su, Caixia, Liu, Rui, Liu, Baoxiu, Khan, Inam Ullah, Xie, Jun, Zhu, Naishuo |
| Předmět: |
|
| Zdroj: |
PLoS ONE; 1/19/2017, Vol. 12 Issue 1, p1-11, 11p |
| Abstrakt: |
Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects. There is a need to develop new and safe adjuvants, because some existing vaccines have low immunogenicity among certain patient groups. In this study, SBP, a hepatitis B surface antigen binding protein that was discovered through screening a human liver cDNA expression library, was introduced into hepatitis B vaccine. A good laboratory practice, non-clinical safety evaluation was performed to identify the side effects of both SBP and SBP-adjuvanted hepatitis B vaccine. The results indicate that SBP could enhance the HBsAg-specific immune response, thus increasing the protection provided by the hepatitis B vaccine. The safety data obtained here warrant further investigation of SBP as a vaccine adjuvant. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
